Skip to main content
SpringerLink
Log in

HAART is the centre of graduated systemic treatment of AIDS-associated Kaposi’s sarcoma

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Hengge UR, Tossing G, Kouri V, et al. Graduated systemic treatment of AIDS-associated Kaposi sarcoma. Am J Cancer 2004; 3(3): 133–49

    Article  CAS  Google Scholar 

  2. Williams AO, Ward JM, Li JF, et al. Immunohistochemical localization of transforming growth factor-β1 in Kaposi’s sarcoma. Hum Pathol 1995; 26: 469–73

    Article  PubMed  CAS  Google Scholar 

  3. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002; 2: 281–92

    Article  PubMed  Google Scholar 

  4. Miles SA. Pathogenesis of human immunodeficiency virus-related Kaposi’s sarcoma. Curr Opin Oncol 1992; 4: 875–82

    Article  PubMed  CAS  Google Scholar 

  5. Cattelan A, Calabro M, Gasperini P, et al. Acquired immune deficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; 28: 44–9

    PubMed  Google Scholar 

  6. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma: associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31: 384–90

    Article  PubMed  CAS  Google Scholar 

  7. Boivin G, Gaudreau A, Routy JP. Evaluation of the human herpes virus 8 DNA load in blood and Kaposi’s sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 2000; 14: 1907–10

    Article  PubMed  CAS  Google Scholar 

  8. Mauss S, Jablonowski H. Efficacy, safety and tolerance of low-dose, long-term interferon-alfa2b and zidovudine in early-stage AIDS-associated Kaposi’s sarcoma. J Acquir Immune Defic Syndr 1995; 2: 157–62

    Google Scholar 

  9. Tossing G. The role of endogenous interferon-alpha in HIV-infec-tion and autoimmune diseases: an overview. In: Aul C, editor. Interferons: biolog activities, clinical efficacy. Berlin Heidelberg: Springer-Verlag, 1997: 14–25

    Google Scholar 

  10. Tossing G. New developments in interferon therapy. Eur J Med Res 2001; 6: 47–65

    PubMed  CAS  Google Scholar 

  11. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–92

    PubMed  CAS  Google Scholar 

  12. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683–91

    PubMed  CAS  Google Scholar 

  13. Northfelt DW, Dezube BJ, Thommes JA. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine (ABV) in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomised phase III clinical trial. J Clin Oncol 1998; 16: 2445–51

    PubMed  CAS  Google Scholar 

  14. Hengge UR, Esser S, Rudel HP, et al. Long-term chemotherapy of HIV-associated Kaposi’s sarcoma with liposomal doxorubicin. Eur J Cancer 2001; 37: 878–83

    Article  PubMed  CAS  Google Scholar 

  15. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996; 14: 2353–64

    PubMed  CAS  Google Scholar 

  16. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of lipsomal daunorubicin (DuanoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol 2002; 25(1): 57–9

    Article  PubMed  Google Scholar 

  17. Tulpule A, Yung RC, Wernz J, et al. Phase II trial of lipsosmal daunorubicin in the treatment of AIDS-related Kaposi sacroma. J Clin Oncol 1998; 16(10): 3369–74

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

HAART is the centre of graduated systemic treatment of AIDS-associated Kaposi’s sarcoma. Drugs Ther. Perspect 21, 14–17 (2005). https://doi.org/10.2165/00042310-200521080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521080-00005

Search

Navigation